In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Summit Therapeutics plc

https://www.summitplc.com/

Latest From Summit Therapeutics plc

Sweet Smell Of Success For Destiny's Anti-MRSA Nasal Gel

Destiny Pharma's XF-73 achieved an "exceptionally high" 99.5% reduction in Staphylococcus aureus bacterial nasal carriage in a mid-stage trial, a result that should attract a number of potential partners for the UK firm.

Infectious Diseases Clinical Trials

30 Rising Leaders In The Life Sciences

Revealed: In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors. Find out who made the cut. 

Business Strategies Commercial

Nanna Acquisition Gives Astellas Mitochondrial Expertise

Japanese firm pays cash plus milestones for UK specialist as it looks to integrate novel screening platform and gain know-how in mitochondrial modulators with potential applications.

Commercial M & A

Summit Therapeutics CEO Applauds UK Antibiotics Market Pilot

The world hopes a UK pilot can offer guidance on making novel antibiotics commercially viable, Summit Therapeutics CEO tells Scrip, but adds his lead asset won’t take part this time. 

Companies Research & Development
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Drug Discovery Tools
      • ADMET
  • Other Names / Subsidiaries
    • Summit Corporation plc
    • VASTox plc
    • Discuva Limited
UsernamePublicRestriction

Register